The contribution of transgenic and nontransgenic animal models in Alzheimer’s disease drug research and development

Emanuela Mhillaj, Vincenzo Cuomo, Cesare Mancuso

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Over the last few years, several papers have become available in the literature on both the main hallmarks of Alzheimer’s disease (AD) and the several intracellular pathways whose alteration is responsible for its onset and progression. The use of transgenic and nontransgenic animal models has played a key role in achieving such a remarkable amount of preclinical data, allowing researchers to dissect the cellular changes occurring in the AD brain. In addition, the huge amount of preclinical evidence arising from these animal models was necessary for the further clinical development of pharmacological agents capable of interfering with most of the impaired neural pathways in AD patients. In this respect, a significant role is played by the dysfunction of excitatory and inhibitory neurotransmission responsible for the cognitive and behavioral symptoms described in AD patients. The aim of this review is to summarize the main animal models that contributed toward unraveling the pathological changes in neurotransmitter synthesis, release, and receptor binding in AD preclinical studies. The review also provides an updated description of the current pharmacological agents – still under clinical development – acting on the neurotransmitter systems.
Original languageEnglish
Pages (from-to)95-111
Number of pages17
JournalBehavioural Pharmacology
Volume28
DOIs
Publication statusPublished - 2017

Keywords

  • Pharmacology
  • Psychiatry and Mental Health

Fingerprint

Dive into the research topics of 'The contribution of transgenic and nontransgenic animal models in Alzheimer’s disease drug research and development'. Together they form a unique fingerprint.

Cite this